Results 71 to 80 of about 6,645 (195)

Completed suicide in patients with skin disease: A systematic review and meta‐analysis

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 1, Page 46-58, January 2026.
Several skin diseases have been associated with suicidality. However, the term ‘suicidality’ encompasses ideation, which weakens the conclusions. In contrast, the much stronger endpoint of completed suicide and skin disease remains ambiguous. This was the focus of this study.
B. Hrvatin Stancic, M. A. S. Henning, N. Eriksen, J. Emilie Dornonville de la Cour, D. M. L. Saunte, G. B. E. Jemec   +5 more
wiley   +1 more source

Dupilumab for recalcitrant prurigo nodularis: Case report

Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2022
Dupilumab is a recombinant fully human monoclonal antibody modulating the signaling of the interleukin (IL)—4 and IL-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis.
Joel Reis, Inês Raposo, Manuela Selores
doaj  

Prurigo Nodularis [PDF]

Proceedings of the Royal Society of Medicine, 1950
W P, ELFORD, F P, WEBER
openaire   +2 more sources

Efficacy and Safety of Tofacitinib in Patients With Refractory Prurigo Nodularis: A 16‐Week, Single‐Center, Prospective, Observational Pilot Study

Dermatologic Therapy
Background: The current management for prurigo nodularis (PN) is challenging. Tofacitinib may emerge as a promising treatment for PN.Aim: This study aimed to assess the efficacy and safety of tofacitinib in treating refractory PN.Design and methods: A 16‐
Ru Dai, Chao-Cheng Chi, Yuchen Lou, I-Jung Hsieh, X. Man   +4 more
semanticscholar   +1 more source

Case report: Dupilumab-induced linear psoriasis: a rare presentation

Frontiers in Medicine
A 42 year-old male with prurigo nodularis treated with dupilumab showed a case of linear psoriasis, highlighting the potential of dupilumab to induce immune shift and chimeric gene expression.
Wen Sun, Kexin Wang, Yuekang Ren, Huajie Yuan, Xiaoqing Lang, Shuping Guo, Hongye Liu   +6 more
doaj   +1 more source

Dupilumab in moderate‐to‐severe prurigo nodularis: Real‐world data from early access program

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Marie Jachiet, Clémentine Toussaint, Valérie Dorizy‐Vuong, Sophie Osdoit, Pierre‐André Becherel, Emmanuelle Amazan, Julia Vanlerberghe, Mahtab Samimi, Claudia Soares Barbosa, Carine Vera, Simmi Wiggins, Véronique Marcadé Fulcrand, Cédric Meyer, Laurent Misery, Jean‐David Bouaziz   +14 more
wiley   +1 more source

Immunotargets and Therapy for Prurigo Nodularis

ImmunoTargets and Therapy, 2022
Angelina Labib, Teresa Ju, Ashley Vander Does, Gil Yosipovitch Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami Miller School of Medicine, Miami, FL, USACorrespondence: Gil Yosipovitch, Dr ...
Labib A, Ju T, Vander Does A, Yosipovitch G   +3 more
doaj  

Enhanced PIEZO1 expression in mast cells of mastocytosis skin lesions: Relevance to Darier's sign

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Yoshiaki Kobayashi, Nobuhiro Nakano, Nguyen Quoc Vuong Tran, Yuki Nakamura, Lisa Minai, Takashi Okamoto, Daiki Nakagomi, Tatsuki R. Kataoka, Tatsuyoshi Kawamura, Atsuhito Nakao   +9 more
wiley   +1 more source

The Risk of Immune‐Mediated Skin Disease Under Dipeptidyl‐Peptidase IV Inhibitor: A Global Population‐Based Study

International Journal of Dermatology, Volume 65, Issue 2, Page 356-358, February 2026.
Noor Mruwat, Noga Givon‐Lavi, Ralf J. Ludwig, Khalaf Kridin   +3 more
wiley   +1 more source

Chronic Prurigo of Nodular Type: A Review

Acta Dermato-Venereologica, 2017
Prurigo nodularis (PN) is a subtype of chronic prurigo presenting single to multiple symmetrically distributed, hyperkeratotic and intensively itching papules and nodules.
Claudia Zeidler, Athanasios Tsianakas, Manuel Pereira, Hartmut Ständer, Gil Yosipovitch, Sonja Ständer   +5 more
doaj   +1 more source